StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

For fiscal 2013 it was $1.14M, down 42.8% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2013Dec 31, 2013$1.14M-42.8%
FY2012Dec 31, 2012$1.99M-38.4%
FY2011Dec 31, 2011$3.23M+5.5%
FY2010Dec 31, 2010$3.06M–

More Gyre Therapeutics figures

See a number that looks wrong?